CytomX Therapeutics Inc (CTMX) CFO Sells $84,360.00 in Stock

CytomX Therapeutics Inc (NASDAQ:CTMX) CFO Debanjan Ray sold 3,000 shares of the firm’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $28.12, for a total transaction of $84,360.00. Following the transaction, the chief financial officer now directly owns 7,741 shares in the company, valued at $217,676.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Debanjan Ray also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, March 2nd, Debanjan Ray sold 33,000 shares of CytomX Therapeutics stock. The stock was sold at an average price of $29.99, for a total transaction of $989,670.00.
  • On Thursday, February 1st, Debanjan Ray sold 2,548 shares of CytomX Therapeutics stock. The stock was sold at an average price of $26.69, for a total transaction of $68,006.12.

Shares of CTMX stock opened at $27.74 on Friday. CytomX Therapeutics Inc has a 52 week low of $13.00 and a 52 week high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.45. The firm had revenue of $27.07 million during the quarter, compared to the consensus estimate of $10.70 million. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%. sell-side analysts forecast that CytomX Therapeutics Inc will post -1.44 EPS for the current year.

CTMX has been the topic of several research reports. Jefferies Group lifted their price objective on shares of CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Bank of America lifted their price objective on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Cantor Fitzgerald set a $40.00 price objective on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 8th. Citigroup initiated coverage on shares of CytomX Therapeutics in a research report on Friday, January 5th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, BidaskClub raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.86.

Several institutional investors and hedge funds have recently bought and sold shares of CTMX. Macquarie Group Ltd. purchased a new position in shares of CytomX Therapeutics in the third quarter worth about $107,000. Bank of Montreal Can purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth about $124,000. MetLife Investment Advisors LLC purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth about $245,000. Virtus Fund Advisers LLC purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth about $339,000. Finally, Alambic Investment Management L.P. purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth about $355,000. Hedge funds and other institutional investors own 78.07% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “CytomX Therapeutics Inc (CTMX) CFO Sells $84,360.00 in Stock” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3338078/cytomx-therapeutics-inc-ctmx-cfo-sells-84360-00-in-stock.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Positive Media Coverage Somewhat Unlikely to Affect Banco Bilbao Vizcaya Argentaria  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Banco Bilbao Vizcaya Argentaria Stock Price
Marriott International  Receiving Somewhat Favorable Media Coverage, Report Finds
Marriott International Receiving Somewhat Favorable Media Coverage, Report Finds
Somewhat Positive News Coverage Somewhat Unlikely to Affect Raytheon  Share Price
Somewhat Positive News Coverage Somewhat Unlikely to Affect Raytheon Share Price
Augur Trading Up 38.2% Over Last Week
Augur Trading Up 38.2% Over Last Week
bitqy 1-Day Trading Volume Tops $2,634.00
bitqy 1-Day Trading Volume Tops $2,634.00
Genaro Network Achieves Market Capitalization of $96.49 Million
Genaro Network Achieves Market Capitalization of $96.49 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.